PURPOSE: To define copy number alterations and gene expression signatures underlying pediatric high-grade glioma (HGG). PATIENTS AND METHODS: We conducted a high-resolution analysis of genomic imbalances in 78 de novo pediatric HGGs, including seven diffuse intrinsic pontine gliomas, and 10 HGGs arising in children who received cranial irradiation for a previous cancer using single nucleotide polymorphism microarray analysis. Gene expression was analyzed with gene expression microarrays for 53 tumors. Results were compared with publicly available data from adult tumors. RESULTS: Significant differences in copy number alterations distinguish childhood and adult glioblastoma. PDGFRA was the predominant target of focal amplification in childhood HGG, including diffuse intrinsic pontine gliomas, and gene expression analyses supported an important role for deregulated PDGFRalpha signaling in pediatric HGG. No IDH1 hotspot mutations were found in pediatric tumors, highlighting molecular differences with adult secondary glioblastoma. Pediatric and adult glioblastomas were clearly distinguished by frequent gain of chromosome 1q (30% v 9%, respectively) and lower frequency of chromosome 7 gain (13% v 74%, respectively) and 10q loss (35% v 80%, respectively). PDGFRA amplification and 1q gain occurred at significantly higher frequency in irradiation-induced tumors, suggesting that these are initiating events in childhood gliomagenesis. A subset of pediatric HGGs showed minimal copy number changes. CONCLUSION: Integrated molecular profiling showed substantial differences in the molecular features underlying pediatric and adult HGG, indicating that findings in adult tumors cannot be simply extrapolated to younger patients. PDGFRalpha may be a useful target for pediatric HGG, including diffuse pontine gliomas.
PURPOSE: To define copy number alterations and gene expression signatures underlying pediatric high-grade glioma (HGG). PATIENTS AND METHODS: We conducted a high-resolution analysis of genomic imbalances in 78 de novo pediatric HGGs, including seven diffuse intrinsic pontine gliomas, and 10 HGGs arising in children who received cranial irradiation for a previous cancer using single nucleotide polymorphism microarray analysis. Gene expression was analyzed with gene expression microarrays for 53 tumors. Results were compared with publicly available data from adult tumors. RESULTS: Significant differences in copy number alterations distinguish childhood and adult glioblastoma. PDGFRA was the predominant target of focal amplification in childhood HGG, including diffuse intrinsic pontine gliomas, and gene expression analyses supported an important role for deregulated PDGFRalpha signaling in pediatric HGG. No IDH1 hotspot mutations were found in pediatric tumors, highlighting molecular differences with adult secondary glioblastoma. Pediatric and adult glioblastomas were clearly distinguished by frequent gain of chromosome 1q (30% v 9%, respectively) and lower frequency of chromosome 7 gain (13% v 74%, respectively) and 10q loss (35% v 80%, respectively). PDGFRA amplification and 1q gain occurred at significantly higher frequency in irradiation-induced tumors, suggesting that these are initiating events in childhood gliomagenesis. A subset of pediatric HGGs showed minimal copy number changes. CONCLUSION: Integrated molecular profiling showed substantial differences in the molecular features underlying pediatric and adult HGG, indicating that findings in adult tumors cannot be simply extrapolated to younger patients. PDGFRalpha may be a useful target for pediatric HGG, including diffuse pontine gliomas.
Authors: S Hing; Y J Lu; B Summersgill; L King-Underwood; J Nicholson; P Grundy; R Grundy; M Gessler; J Shipley; K Pritchard-Jones Journal: Am J Pathol Date: 2001-02 Impact factor: 4.307
Authors: Ian F Pollack; Ronald L Hamilton; C David James; Sydney D Finkelstein; Judith Burnham; Allan J Yates; Emiko J Holmes; Tianni Zhou; Jonathan L Finlay Journal: J Neurosurg Date: 2006-11 Impact factor: 5.115
Authors: Erica L Jackson; Jose Manuel Garcia-Verdugo; Sara Gil-Perotin; Monica Roy; Alfredo Quinones-Hinojosa; Scott VandenBerg; Arturo Alvarez-Buylla Journal: Neuron Date: 2006-07-20 Impact factor: 17.173
Authors: A W Walter; M L Hancock; C H Pui; M M Hudson; J S Ochs; G K Rivera; C B Pratt; J M Boyett; L E Kun Journal: J Clin Oncol Date: 1998-12 Impact factor: 44.544
Authors: M Carter; J Nicholson; F Ross; J Crolla; R Allibone; V Balaji; R Perry; D Walker; R Gilbertson; D W Ellison Journal: Br J Cancer Date: 2002-03-18 Impact factor: 7.640
Authors: Koichi Ichimura; Danita M Pearson; Sylvia Kocialkowski; L Magnus Bäcklund; Raymond Chan; David T W Jones; V Peter Collins Journal: Neuro Oncol Date: 2009-05-12 Impact factor: 12.300
Authors: Barbara S Paugh; Alberto Broniscer; Chunxu Qu; Claudia P Miller; Junyuan Zhang; Ruth G Tatevossian; James M Olson; J Russell Geyer; Susan N Chi; Nasjla Saba da Silva; Arzu Onar-Thomas; Justin N Baker; Amar Gajjar; David W Ellison; Suzanne J Baker Journal: J Clin Oncol Date: 2011-09-19 Impact factor: 44.544
Authors: Viola Caretti; A Charlotte P Sewing; Tonny Lagerweij; Pepijn Schellen; Marianna Bugiani; Marc H A Jansen; Dannis G van Vuurden; Anna C Navis; Ilona Horsman; W Peter Vandertop; David P Noske; Pieter Wesseling; Gertjan J L Kaspers; Javad Nazarian; Hannes Vogel; Esther Hulleman; Michelle Monje; Thomas Wurdinger Journal: Acta Neuropathol Date: 2014-04-29 Impact factor: 17.088
Authors: Christopher L Tinkle; Elizabeth C Duncan; Mikhail Doubrovin; Yuanyuan Han; Yimei Li; Hyun Kim; Alberto Broniscer; Scott E Snyder; Thomas E Merchant; Barry L Shulkin Journal: J Nucl Med Date: 2018-08-02 Impact factor: 10.057
Authors: Amar Gajjar; Roger J Packer; N K Foreman; Kenneth Cohen; Daphne Haas-Kogan; Thomas E Merchant Journal: Pediatr Blood Cancer Date: 2012-12-19 Impact factor: 3.167